메뉴 건너뛰기




Volumn 18, Issue 7, 2018, Pages

Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA

Author keywords

Cardioprotection; GLP 1RA; Hemodynamics; SGLT2i; Type 2 diabetes; Vascular pathophysiology

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; IPRAGLIFLOZIN; LIRAGLUTIDE; LIXISENATIDE; LUSEOGLIFLOZIN; PIOGLITAZONE; PLACEBO; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; CARDIOTONIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

EID: 85048492438     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-018-1011-7     Document Type: Review
Times cited : (41)

References (161)
  • 2
    • 85048496079 scopus 로고    scopus 로고
    • Statistics | cdc.gov [Internet]
    • Heart Disease Facts & Statistics | cdc.gov [Internet]. [cited 2017 Dec 1].
    • (2017) [cited
  • 3
    • 85048497457 scopus 로고    scopus 로고
    • Clinical, Pathology. Google Books [Internet]
    • Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology. Google Books [Internet]. [cited 2017 Dec 1].
    • (2017) [cited
    • Failure, C.H.1    Transplantation, C.2
  • 4
    • 84873848690 scopus 로고    scopus 로고
    • Myocardial ischemia-reperfusion injury: a neglected therapeutic target
    • PID: 23281415
    • Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123:92–100.
    • (2013) J Clin Invest , vol.123 , pp. 92-100
    • Hausenloy, D.J.1    Yellon, D.M.2
  • 5
    • 54049144185 scopus 로고    scopus 로고
    • Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy
    • PID: 18716709
    • Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol. 2008;103:501–13.
    • (2008) Basic Res Cardiol , vol.103 , pp. 501-513
    • Miura, T.1    Miki, T.2
  • 6
    • 84927559910 scopus 로고    scopus 로고
    • Association of obesity and long-term mortality in patients with acute myocardial infarction with and without diabetes mellitus: results from the MONICA/KORA myocardial infarction registry CARDIO VASCULAR DIABETOLOGY
    • Giovanna Colombo M, Meisinger C, Amann U, Heier M, von Scheidt W, Kuch B, et al. Association of obesity and long-term mortality in patients with acute myocardial infarction with and without diabetes mellitus: results from the MONICA/KORA myocardial infarction registry CARDIO VASCULAR DIABETOLOGY. Cardiovasc Diabetol. 2015;14.
    • (2015) Cardiovasc Diabetol , pp. 14
    • Giovanna Colombo, M.1    Meisinger, C.2    Amann, U.3    Heier, M.4    von Scheidt, W.5    Kuch, B.6
  • 7
    • 84864979991 scopus 로고    scopus 로고
    • Type 2 diabetes mellitus: a review of current trends
    • PID: 23071876 1
    • Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27:269–73. Available: http://www.ncbi.nlm.nih.gov/pubmed/23071876 (accessed 2017 Dec 1)
    • (2012) Oman Med J , vol.27 , pp. 269-273
    • Olokoba, A.B.1    Obateru, O.A.2    Olokoba, L.B.3
  • 8
    • 55849120862 scopus 로고    scopus 로고
    • Epidemiology of diabetes and diabetes-related complications
    • PID: 18801858 1
    • Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88:1254–64. Available: http://www.ncbi.nlm.nih.gov/pubmed/18801858 (accessed 2017 Dec 1)
    • (2008) Phys Ther , vol.88 , pp. 1254-1264
    • Deshpande, A.D.1    Harris-Hayes, M.2    Schootman, M.3
  • 9
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 diabetes
    • Group TA to CCR in DS. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. Available: http://www.nejm.org/doi/abs/10.1056/NEJMoa0802743 (accessed 2017 Dec 1)
    • (2008) N Engl J Med , vol.358 , pp. 2545-2559
  • 10
    • 84860117993 scopus 로고    scopus 로고
    • Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
    • PID: 19959591 23
    • Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731. Available: http://www.ncbi.nlm.nih.gov/pubmed/19959591 (accessed 2017 Apr 23)
    • (2009) BMJ , vol.339 , pp. b4731
    • Tzoulaki, I.1    Molokhia, M.2    Curcin, V.3    Little, M.P.4    Millett, C.J.5    Ng, A.6    Hughes, R.I.7    Khunti, K.8    Wilkins, M.R.9    Majeed, A.10    Elliott, P.11
  • 11
    • 79953203593 scopus 로고    scopus 로고
    • Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
    • PID: 21415101 23
    • Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309. Available: http://www.ncbi.nlm.nih.gov/pubmed/21415101 (accessed 2017 Apr 23)
    • (2011) BMJ , vol.342 , pp. d1309
    • Loke, Y.K.1    Kwok, C.S.2    Singh, S.3
  • 12
    • 75149128665 scopus 로고    scopus 로고
    • Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits
    • PID: 20103558 23
    • Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33:428–33. Available: http://www.ncbi.nlm.nih.gov/pubmed/20103558 (accessed 2017 Apr 23)
    • (2010) Diabetes Care , vol.33 , pp. 428-433
    • Drucker, D.J.1    Sherman, S.I.2    Gorelick, F.S.3    Bergenstal, R.M.4    Sherwin, R.S.5    Buse, J.B.6
  • 19
    • 45149118855 scopus 로고    scopus 로고
    • Intensive glycemic control in the ACCORD and ADVANCE trials
    • PID: 18539918
    • Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630–3. Available: http://www.nejm.org/doi/abs/10.1056/NEJMe0804182 (accessed 2017 Dec 1)
    • (2008) N Engl J Med , vol.358 , pp. 2630-2633
    • Dluhy, R.G.1    McMahon, G.T.2
  • 20
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    • 1
    • ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72. Available: http://www.ncbi.nlm.nih.gov/pubmed/18539916 (accessed 2017 Dec 1)
    • (2008) N Engl J Med , vol.358 , pp. 2560-2572
    • Patel, A.1    MacMahon, S.2    Chalmers, J.3    Neal, B.4    Billot, L.5
  • 21
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 diabetes
    • 23
    • Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. Available: http://www.ncbi.nlm.nih.gov/pubmed/18539917 (accessed 2017 Apr 23)
    • (2008) N Engl J Med , vol.358 , pp. 2545-2559
    • Gerstein, H.C.1    Miller, M.E.2    Byington, R.P.3    Goff, D.C.4    Bigger, J.T.5
  • 23
    • 34548303246 scopus 로고    scopus 로고
    • The rosiglitazone story—lessons from an FDA advisory committee meeting
    • PID: 17687124 1
    • Rosen CJ. The rosiglitazone story—lessons from an FDA advisory committee meeting. N Engl J Med. 2007;357:844–6. Available: http://www.ncbi.nlm.nih.gov/pubmed/17687124 (accessed 2017 Dec 1)
    • (2007) N Engl J Med , vol.357 , pp. 844-846
    • Rosen, C.J.1
  • 24
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • PID: 17517853 1
    • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71. Available: http://www.ncbi.nlm.nih.gov/pubmed/17517853 (accessed 2017 Dec 1)
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 25
    • 84884930937 scopus 로고    scopus 로고
    • The cardiovascular safety of diabetes drugs—insights from the rosiglitazone experience
    • PID: 23992603
    • Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs—insights from the rosiglitazone experience. N Engl J Med. 2013;369:1285–7. Available: http://www.nejm.org/doi/10.1056/NEJMp1309610 (accessed 2017 Dec 1)
    • (2013) N Engl J Med , vol.369 , pp. 1285-1287
    • Hiatt, W.R.1    Kaul, S.2    Smith, R.J.3
  • 26
    • 84992453325 scopus 로고    scopus 로고
    • Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure
    • PID: 27599528 1
    • Kimura G. Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure. Circ J. 2016;80:2277–81. Available: http://www.ncbi.nlm.nih.gov/pubmed/27599528 (accessed 2017 Dec 1)
    • (2016) Circ J , vol.80 , pp. 2277-2281
    • Kimura, G.1
  • 27
    • 84964773926 scopus 로고    scopus 로고
    • SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
    • PID: 27208375 1
    • Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717–25. Available: http://www.ncbi.nlm.nih.gov/pubmed/27208375 (accessed 2017 Dec 1)
    • (2016) Diabetes Care , vol.39 , pp. 717-725
    • Abdul-Ghani, M.1    Del Prato, S.2    Chilton, R.3    DeFronzo, R.A.4
  • 28
    • 84992358035 scopus 로고    scopus 로고
    • The cardiovascular biology of glucagon-like peptide-1
    • PID: 27345422 1
    • Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15–30. Available: http://www.ncbi.nlm.nih.gov/pubmed/27345422 (accessed 2017 Dec 1)
    • (2016) Cell Metab , vol.24 , pp. 15-30
    • Drucker, D.J.1
  • 29
    • 85020473445 scopus 로고    scopus 로고
    • Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
    • PID: 28432726
    • DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19:1353–62. Available: http://doi.wiley.com/10.1111/dom.12982 (accessed 2017 Dec 1)
    • (2017) Diabetes Obes Metab , vol.19 , pp. 1353-1362
    • DeFronzo, R.A.1
  • 30
    • 77951151612 scopus 로고    scopus 로고
    • Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4
    • PID: 20068138
    • Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59:1030–7. Available: http://diabetes.diabetesjournals.org/cgi/doi/10.2337/db09-1694 (accessed 2017 Dec 10)
    • (2010) Diabetes , vol.59 , pp. 1030-1037
    • Arakawa, M.1    Mita, T.2    Azuma, K.3    Ebato, C.4    Goto, H.5    Nomiyama, T.6    Fujitani, Y.7    Hirose, T.8    Kawamori, R.9    Watada, H.10
  • 31
    • 84879391645 scopus 로고    scopus 로고
    • The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(−/−) mouse model
    • Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(−/−) mouse model. Diabetes Vasc Dis Res. 2013;10:353–60. Available: http://journals.sagepub.com/doi/10.1177/1479164113481817 (accessed 2017 Dec 10)
    • (2013) Diabetes Vasc Dis Res , vol.10 , pp. 353-360
    • Gaspari, T.1    Welungoda, I.2    Widdop, R.E.3    Simpson, R.W.4    Dear, A.E.5
  • 33
    • 84896080822 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
    • PID: 24362727
    • Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O’Connell J, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014;57:781–4. Available: http://link.springer.com/10.1007/s00125-013-3145-0 (accessed 2017 Dec 10)
    • (2014) Diabetologia , vol.57 , pp. 781-784
    • Hogan, A.E.1    Gaoatswe, G.2    Lynch, L.3    Corrigan, M.A.4    Woods, C.5    O’Connell, J.6    O’Shea, D.7
  • 34
    • 84962758670 scopus 로고    scopus 로고
    • Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals
    • PID: 27186361
    • Hirano T, Mori Y. Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals. J Diabetes Investig. 2016;7:80–6.
    • (2016) J Diabetes Investig , vol.7 , pp. 80-86
    • Hirano, T.1    Mori, Y.2
  • 35
    • 84903511924 scopus 로고    scopus 로고
    • Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes
    • PID: 24667461
    • Ceriello A, Novials A, Canivell S, La Sala L, Pujadas G, Esposito K, et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care. 2014;37:1938–43.
    • (2014) Diabetes Care , vol.37 , pp. 1938-1943
    • Ceriello, A.1    Novials, A.2    Canivell, S.3    La Sala, L.4    Pujadas, G.5    Esposito, K.6
  • 36
    • 85020077721 scopus 로고    scopus 로고
    • SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice
    • Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–49. 10.1016/j.ebiom.2017.05.028.
    • (2017) EBioMedicine , vol.20 , pp. 137-149
    • Xu, L.1    Nagata, N.2    Nagashimada, M.3    Zhuge, F.4    Ni, Y.5    Chen, G.6    Mayoux, E.7    Kaneko, S.8    Ota, T.9
  • 37
    • 85021409196 scopus 로고    scopus 로고
    • The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
    • PID: 28667906
    • Steven S, Oelze M, Hanf A, Kröller-schön S, Kashani F, Roohani S, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370–85.
    • (2017) Redox Biol , vol.13 , pp. 370-385
    • Steven, S.1    Oelze, M.2    Hanf, A.3    Kröller-schön, S.4    Kashani, F.5    Roohani, S.6
  • 41
    • 84959511891 scopus 로고    scopus 로고
    • The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
    • Kern M, Klöting N, Mark M, Mayoux E, Klein T, Blüher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016;65:114–23. 10.1016/j.metabol.2015.10.010.
    • (2016) Metabolism , vol.65 , pp. 114-123
    • Kern, M.1    Klöting, N.2    Mark, M.3    Mayoux, E.4    Klein, T.5    Blüher, M.6
  • 42
    • 0034641568 scopus 로고    scopus 로고
    • Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
    • PID: 10938048
    • Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
    • (2000) BMJ , vol.321 , pp. 405-412
    • Stratton, I.M.1    Adler, A.I.2    Neil, H.A.3    Matthews, D.R.4    Manley, S.E.5    Cull, C.A.6    Hadden, D.7    Turner, R.C.8    Holman, R.R.9
  • 44
    • 77953959949 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A
    • PID: 20448207
    • Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Sillje HHW. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010;30:1407–14.
    • (2010) Arterioscler Thromb Vasc Biol , vol.30 , pp. 1407-1414
    • Oeseburg, H.1    de Boer, R.A.2    Buikema, H.3    van der Harst, P.4    van Gilst, W.H.5    Sillje, H.H.W.6
  • 46
    • 84880514665 scopus 로고    scopus 로고
    • LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells
    • PID: 23806684 1
    • Dai Y, Mercanti F, Dai D, Wang X, Ding Z, Pothineni NV, et al. LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells. Biochem Biophys Res Commun. 2013;437:62–6. Available: http://www.ncbi.nlm.nih.gov/pubmed/23806684 (accessed 2017 Dec 1)
    • (2013) Biochem Biophys Res Commun , vol.437 , pp. 62-66
    • Dai, Y.1    Mercanti, F.2    Dai, D.3    Wang, X.4    Ding, Z.5    Pothineni, N.V.6    Mehta, J.L.7
  • 47
    • 84918840480 scopus 로고    scopus 로고
    • Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway
    • 1
    • Zhao L, Li AQ, Zhou TF, Zhang MQ, Qin XM. Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway. AJP Cell Physiol. 2014;307:C1130–41. Available: http://www.ncbi.nlm.nih.gov/pubmed/25298426 (accessed 2017 Dec 1)
    • (2014) AJP Cell Physiol , vol.307 , pp. C1130-C1141
    • Zhao, L.1    Li, A.Q.2    Zhou, T.F.3    Zhang, M.Q.4    Qin, X.M.5
  • 48
    • 84945914015 scopus 로고    scopus 로고
    • Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin II via the inhibition of ERK1/2 and JNK signaling pathways
    • PID: 26379274 1
    • Nagayama K, Kyotani Y, Zhao J, Ito S, Ozawa K, Bolstad FA, et al. Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin II via the inhibition of ERK1/2 and JNK signaling pathways. PLoS One. 2015;10:e0137960. Available: http://www.ncbi.nlm.nih.gov/pubmed/26379274 (accessed 2017 Dec 1)
    • (2015) PLoS One , vol.10
    • Nagayama, K.1    Kyotani, Y.2    Zhao, J.3    Ito, S.4    Ozawa, K.5    Bolstad, F.A.6    Yoshizumi, M.7
  • 49
    • 84924286044 scopus 로고    scopus 로고
    • Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways
    • PID: 25855361 1
    • Shi L, Ji Y, Jiang X, Zhou L, Xu Y, Li Y, et al. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways. Cardiovasc Diabetol. 2015;14:18. Available: http://www.cardiab.com/content/14/1/18 (accessed 2017 Dec 1)
    • (2015) Cardiovasc Diabetol , vol.14 , pp. 18
    • Shi, L.1    Ji, Y.2    Jiang, X.3    Zhou, L.4    Xu, Y.5    Li, Y.6    Jiang, W.7    Meng, P.8    Liu, X.9
  • 51
    • 84974707222 scopus 로고    scopus 로고
    • A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
    • PID: 26818652
    • Takeshige Y, Fujisawa Y, Rahman A, Kittikulsuth W, Nakano D, Mori H, et al. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens Res. 2016;39:415–22. Available: http://www.nature.com/doifinder/10.1038/hr.2016.2 (accessed 2017 Dec 5)
    • (2016) Hypertens Res , vol.39 , pp. 415-422
    • Takeshige, Y.1    Fujisawa, Y.2    Rahman, A.3    Kittikulsuth, W.4    Nakano, D.5    Mori, H.6    Masaki, T.7    Ohmori, K.8    Kohno, M.9    Ogata, H.10    Nishiyama, A.11
  • 52
    • 84961223678 scopus 로고    scopus 로고
    • Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
    • PID: 26982381 1
    • Rahman A, Kittikulsuth W, Fujisawa Y, Sufiun A, Rafiq K, Hitomi H, et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens. 2016;34:893–906. Available: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004872-201605000-00015 (accessed 2017 Dec 1).
    • (2016) J Hypertens , vol.34 , pp. 893-906
    • Rahman, A.1    Kittikulsuth, W.2    Fujisawa, Y.3    Sufiun, A.4    Rafiq, K.5    Hitomi, H.6    Nakano, D.7    Sohara, E.8    Uchida, S.9    Nishiyama, A.10
  • 53
    • 84867136387 scopus 로고    scopus 로고
    • Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
    • PID: 22832924 5
    • Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol. 2012;303:F963–71. Available: http://www.ncbi.nlm.nih.gov/pubmed/22832924 (accessed 2017 Dec 5)
    • (2012) Am J Physiol Renal Physiol , vol.303 , pp. F963-F971
    • Rieg, T.1    Gerasimova, M.2    Murray, F.3    Masuda, T.4    Tang, T.5    Rose, M.6    Drucker, D.J.7    Vallon, V.8
  • 54
    • 84994508611 scopus 로고    scopus 로고
    • • Frías J, Guja C, Hardy E, Ahmed A, Dong F, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotheraprandomised control. Lancet Diabetes Endocrinol. 2016. This study exemplies the notion of combination therapy with GLP-1RA and SGLT2i. The study not only evaluates efficacy and safety of co-initiation of the GLP-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin but also compares it to exenatide or dapagliflozin monotherapy in patients with type 2 diabetes inadequately controlled by metformin.
    • • Frías J, Guja C, Hardy E, Ahmed A, Dong F, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised control. Lancet Diabetes Endocrinol. 2016. This study exemplies the notion of combination therapy with GLP-1RA and SGLT2i. The study not only evaluates efficacy and safety of co-initiation of the GLP-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin but also compares it to exenatide or dapagliflozin monotherapy in patients with type 2 diabetes inadequately controlled by metformin.
    • (2016) a 28 week, multicentre, double-blind, phase 3
  • 55
    • 84943643452 scopus 로고    scopus 로고
    • Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats
    • PID: 26196539 1
    • Romaní-Pérez M, Outeiriño-Iglesias V, Moya CM, Santisteban P, González-Matías LC, Vigo E, et al. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology. 2015;156:3559–69. Available: http://www.ncbi.nlm.nih.gov/pubmed/26196539 (accessed 2017 Dec 1)
    • (2015) Endocrinology , vol.156 , pp. 3559-3569
    • Romaní-Pérez, M.1    Outeiriño-Iglesias, V.2    Moya, C.M.3    Santisteban, P.4    González-Matías, L.C.5    Vigo, E.6    Mallo, F.7
  • 56
    • 84980320178 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
    • PID: 27470878 7
    • Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752–72. Available: http://www.ncbi.nlm.nih.gov/pubmed/27470878 (accessed 2017 Dec 7)
    • (2016) Circulation , vol.134 , pp. 752-772
    • Heerspink, H.J.L.1    Perkins, B.A.2    Fitchett, D.H.3    Husain, M.4    Cherney, D.Z.I.5
  • 59
    • 84964950969 scopus 로고    scopus 로고
    • Possible increase in serum FABP4 level despite adiposity reduction by canagliflozin, an SGLT2 inhibitor
    • Furuhashi M, Matsumoto M, Hiramitsu S, Omori A, Tanaka M, Moniwa N, et al. Possible increase in serum FABP4 level despite adiposity reduction by canagliflozin, an SGLT2 inhibitor. PLoS One. 2016;11:1–13.
    • (2016) PLoS One , vol.11 , pp. 1-13
    • Furuhashi, M.1    Matsumoto, M.2    Hiramitsu, S.3    Omori, A.4    Tanaka, M.5    Moniwa, N.6
  • 60
    • 84958746117 scopus 로고    scopus 로고
    • Cardiometabolic effects of glucagon-like peptide-1 agonists
    • PID: 26782825 15
    • Sarraju A, Kim SH, Knowles JW. Cardiometabolic effects of glucagon-like peptide-1 agonists. Curr Atheroscler Rep. 2016;18:7. Available: http://www.ncbi.nlm.nih.gov/pubmed/26782825 (accessed 2018 Jan 15)
    • (2016) Curr Atheroscler Rep , vol.18 , pp. 7
    • Sarraju, A.1    Kim, S.H.2    Knowles, J.W.3
  • 61
    • 84962110250 scopus 로고    scopus 로고
    • Effect of the GLP-1 receptor agonist lixisenatide on counter-regulatory responses to hypoglycemia in subjects with insulin-treated type 2 diabetes
    • 15
    • Farngren J, Persson M, Ahrén B. Effect of the GLP-1 receptor agonist lixisenatide on counter-regulatory responses to hypoglycemia in subjects with insulin-treated type 2 diabetes. Diabetes Care. 2015;39:dc151274. Available: http://www.ncbi.nlm.nih.gov/pubmed/26537183 (accessed 2018 Jan 15)
    • (2015) Diabetes Care , vol.39 , pp. dc151274
    • Farngren, J.1    Persson, M.2    Ahrén, B.3
  • 64
    • 84908042187 scopus 로고    scopus 로고
    • Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium
    • PID: 25117407
    • DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, et al. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab. 2014;307:E630–43.
    • (2014) Am J Physiol Endocrinol Metab , vol.307 , pp. E630-E643
    • DeNicola, M.1    Du, J.2    Wang, Z.3    Yano, N.4    Zhang, L.5    Wang, Y.6
  • 65
    • 84939540746 scopus 로고    scopus 로고
    • Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart
    • PID: 26098939
    • Aravindhan K, Bao W, Harpel MR, Willette RN, Lepore JJ, Jucker BM. Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart. PLoS One. 2015;10:e0130894.
    • (2015) PLoS One , vol.10
    • Aravindhan, K.1    Bao, W.2    Harpel, M.R.3    Willette, R.N.4    Lepore, J.J.5    Jucker, B.M.6
  • 66
    • 84879369264 scopus 로고    scopus 로고
    • Investigation of the protective effects of phlorizin on diabetic cardiomyopathy in db/db mice by quantitative proteomics
    • PID: 23671862
    • Cai Q, Li B, Yu F, Lu W, Zhang Z, Yin M, et al. Investigation of the protective effects of phlorizin on diabetic cardiomyopathy in db/db mice by quantitative proteomics. J Diabetes Res. 2013;2013:263845.
    • (2013) J Diabetes Res , vol.2013 , pp. 263845
    • Cai, Q.1    Li, B.2    Yu, F.3    Lu, W.4    Zhang, Z.5    Yin, M.6
  • 67
    • 84975789692 scopus 로고    scopus 로고
    • Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism
    • PID: 27207551
    • Briand F, Mayoux E, Brousseau E, Burr N, Urbain I, Costard C, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032–8.
    • (2016) Diabetes , vol.65 , pp. 2032-2038
    • Briand, F.1    Mayoux, E.2    Brousseau, E.3    Burr, N.4    Urbain, I.5    Costard, C.6    Mark, M.7    Sulpice, T.8
  • 69
    • 64649102619 scopus 로고    scopus 로고
    • GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
    • PID: 19151200
    • Noyan-Ashraf MH, Abdul Momen M, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975–83.
    • (2009) Diabetes , vol.58 , pp. 975-983
    • Noyan-Ashraf, M.H.1    Abdul Momen, M.2    Ban, K.3    Sadi, A.M.4    Zhou, Y.Q.5    Riazi, A.M.6
  • 70
    • 84961057126 scopus 로고    scopus 로고
    • Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation
    • PID: 26158396
    • Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2016;48:191–5.
    • (2016) Horm Metab Res , vol.48 , pp. 191-195
    • Ishibashi, Y.1    Matsui, T.2    Yamagishi, S.3
  • 73
    • 84962144694 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 (SGLT2) plays as a physiological glucose sensor and regulates cellular contractility in rat mesangial cells
    • Wakisaka M, Nagao T, Yoshinari M. Sodium glucose cotransporter 2 (SGLT2) plays as a physiological glucose sensor and regulates cellular contractility in rat mesangial cells. PLoS One. 2016;11:1–15.
    • (2016) PLoS One , vol.11 , pp. 1-15
    • Wakisaka, M.1    Nagao, T.2    Yoshinari, M.3
  • 74
    • 85016037090 scopus 로고    scopus 로고
    • Exendin-4 inhibits structural remodeling and improves Ca 2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway
    • PID: 28242257 15
    • Chen J, Wang D, Wang F, Shi S, Chen Y, Yang B, et al. Exendin-4 inhibits structural remodeling and improves Ca 2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway. Peptides. 2017;90:69–77. Available: http://linkinghub.elsevier.com/retrieve/pii/S0196978117300499 (accessed 2018 Jan 15)
    • (2017) Peptides , vol.90 , pp. 69-77
    • Chen, J.1    Wang, D.2    Wang, F.3    Shi, S.4    Chen, Y.5    Yang, B.6    Tang, Y.7    Huang, C.8
  • 75
    • 84877252041 scopus 로고    scopus 로고
    • Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a
    • 15
    • Younce CW, Burmeister MA, Ayala JE. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Physiol. 2013;304:C508–18. Available: http://www.ncbi.nlm.nih.gov/pubmed/23302777 (accessed 2018 Jan 15)
    • (2013) Am J Physiol Physiol , vol.304 , pp. C508-C518
    • Younce, C.W.1    Burmeister, M.A.2    Ayala, J.E.3
  • 76
    • 84964703072 scopus 로고    scopus 로고
    • Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess?
    • PID: 27208377
    • Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care. 2016;39:738–42. Available: http://care.diabetesjournals.org/lookup/doi/10.2337/dc15-2237 (accessed 2017 Dec 1)
    • (2016) Diabetes Care , vol.39 , pp. 738-742
    • Smith, R.J.1    Goldfine, A.B.2    Hiatt, W.R.3
  • 78
    • 10744225665 scopus 로고    scopus 로고
    • Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction
    • PID: 14662734
    • Frantz S, Hu K, Widder J, Bayer B, Witzel CC, Schmidt I, et al. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol. 2004;141:9–14. Available: http://onlinelibrary.wiley.com/store/10.1038/sj.bjp.0705585/asset/sj.bjp.0705585.pdf;jsessionid=5A70CB66C4175CC0884D1F6E08E5C911.f01t01?v=1&t=j2o3a0tk&s=26aa795ad4833291736e0970513e411caac037af (accessed 2017 May 13)
    • (2004) Br J Pharmacol , vol.141 , pp. 9-14
    • Frantz, S.1    Hu, K.2    Widder, J.3    Bayer, B.4    Witzel, C.C.5    Schmidt, I.6    Galuppo, P.7    Strotmann, J.8    Ertl, G.9    Bauersachs, J.10
  • 80
    • 79953236112 scopus 로고    scopus 로고
    • Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus
    • PID: 21294599 13
    • Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus. Am J Cardiovasc Drugs. 2011;11:115–28. Available: http://www.ncbi.nlm.nih.gov/pubmed/21294599 (accessed 2017 May 13)
    • (2011) Am J Cardiovasc Drugs , vol.11 , pp. 115-128
    • Hernandez, A.V.1    Usmani, A.2    Rajamanickam, A.3    Moheet, A.4
  • 81
    • 84930675015 scopus 로고    scopus 로고
    • Thiazolidinediones and edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention
    • PID: 26074951 13
    • Horita S, Nakamura M, Satoh N, Suzuki M, Seki G. Thiazolidinediones and edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention. PPAR Res. 2015;2015:646423. Available: http://www.ncbi.nlm.nih.gov/pubmed/26074951 (accessed 2017 May 13)
    • (2015) PPAR Res , vol.2015 , pp. 646423
    • Horita, S.1    Nakamura, M.2    Satoh, N.3    Suzuki, M.4    Seki, G.5
  • 82
    • 67149146438 scopus 로고    scopus 로고
    • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
    • PID: 19501900 13
    • Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–35. Available: http://www.ncbi.nlm.nih.gov/pubmed/19501900 (accessed 2017 May 13)
    • (2009) Lancet , vol.373 , pp. 2125-2135
    • Home, P.D.1    Pocock, S.J.2    Beck-Nielsen, H.3    Curtis, P.S.4    Gomis, R.5    Hanefeld, M.6    Jones, N.P.7    Komajda, M.8    McMurray, J.J.V.9
  • 83
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial
    • PID: 16214598 1
    • Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–89. Available: http://www.ncbi.nlm.nih.gov/pubmed/16214598 (accessed 2017 Dec 1)
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3    Erdmann, E.4    Massi-Benedetti, M.5    Moules, I.K.6
  • 84
    • 85009136703 scopus 로고    scopus 로고
    • Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
    • PID: 28057658 1
    • Liao H-W, Saver JL, Wu Y-L, Chen T-H, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7:e013927. Available: http://www.ncbi.nlm.nih.gov/pubmed/28057658 (accessed 2017 Dec 1)
    • (2017) BMJ Open , vol.7
    • Liao, H.-W.1    Saver, J.L.2    Wu, Y.-L.3    Chen, T.-H.4    Lee, M.5    Ovbiagele, B.6
  • 85
  • 86
    • 0034735992 scopus 로고    scopus 로고
    • Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
    • PID: 11095972 2
    • Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun. 2000;278:704–11. Available: http://www.ncbi.nlm.nih.gov/pubmed/11095972 (accessed 2017 Dec 2)
    • (2000) Biochem Biophys Res Commun , vol.278 , pp. 704-711
    • Sakamoto, J.1    Kimura, H.2    Moriyama, S.3    Odaka, H.4    Momose, Y.5    Sugiyama, Y.6    Sawada, H.7
  • 87
    • 0037784011 scopus 로고    scopus 로고
    • GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine
    • PID: 12832109 1
    • Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept. 2003;114:189–96. Available: http://www.ncbi.nlm.nih.gov/pubmed/12832109 (accessed 2017 Dec 1)
    • (2003) Regul Pept , vol.114 , pp. 189-196
    • Mortensen, K.1    Christensen, L.L.2    Holst, J.J.3    Orskov, C.4
  • 88
    • 33746467477 scopus 로고    scopus 로고
    • The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis
    • PID: 16888147 1
    • BRUBAKER PL. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci. 2006;1070:10–26. Available: http://www.ncbi.nlm.nih.gov/pubmed/16888147 (accessed 2017 Dec 1)
    • (2006) Ann N Y Acad Sci , vol.1070 , pp. 10-26
    • Brubaker, P.1
  • 90
    • 84922771356 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications
    • PID: 25349901 1
    • Manandhar B, Ahn J-M. Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications. J Med Chem. 2015;58:1020–37. Available: http://www.ncbi.nlm.nih.gov/pubmed/25349901 (accessed 2017 Dec 1)
    • (2015) J Med Chem , vol.58 , pp. 1020-1037
    • Manandhar, B.1    Ahn, J.-M.2
  • 91
    • 84959871979 scopus 로고    scopus 로고
    • Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
    • PID: 26511102 1
    • Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18:317–32. Available: http://www.ncbi.nlm.nih.gov/pubmed/26511102 (accessed 2017 Dec 1)
    • (2016) Diabetes Obes Metab , vol.18 , pp. 317-332
    • Madsbad, S.1
  • 96
    • 80052362968 scopus 로고    scopus 로고
    • Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
    • PID: 21606218
    • Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515–31. Available: https://academic.oup.com/edrv/article-lookup/doi/10.1210/er.2010-0029 (accessed 2017 Dec 1)
    • (2011) Endocr Rev , vol.32 , pp. 515-531
    • Abdul-Ghani, M.A.1    Norton, L.2    DeFronzo, R.A.3
  • 97
    • 0141706702 scopus 로고    scopus 로고
    • Protein tyrosine nitration in the mitochondria from diabetic mouse heart: implications to dysfunctional mitochondria in diabetes
    • PID: 12821649 22
    • Turko IV, Li L, Aulak KS, Stuehr DJ, Chang J-Y, Murad F. Protein tyrosine nitration in the mitochondria from diabetic mouse heart: implications to dysfunctional mitochondria in diabetes. J Biol Chem. 2003;278:33972–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/12821649 (accessed 2017 Apr 22)
    • (2003) J Biol Chem , vol.278 , pp. 33972-33977
    • Turko, I.V.1    Li, L.2    Aulak, K.S.3    Stuehr, D.J.4    Chang, J.-Y.5    Murad, F.6
  • 99
    • 78651349221 scopus 로고    scopus 로고
    • Biology of human sodium glucose transporters
    • PID: 21527736 1
    • Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–94. Available: http://www.ncbi.nlm.nih.gov/pubmed/21527736 (accessed 2017 Dec 1)
    • (2011) Physiol Rev , vol.91 , pp. 733-794
    • Wright, E.M.1    Loo, D.D.F.2    Hirayama, B.A.3
  • 100
    • 75749094398 scopus 로고    scopus 로고
    • Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target
    • PID: 19965550 1
    • Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5:133–41. Available: http://www.ncbi.nlm.nih.gov/pubmed/19965550 (accessed 2017 Dec 1)
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 133-141
    • Santer, R.1    Calado, J.2
  • 102
    • 84892576563 scopus 로고    scopus 로고
    • Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
    • 1
    • Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. AJP Ren Physiol. 2014;306:F188–93. Available: http://www.ncbi.nlm.nih.gov/pubmed/24226519 (accessed 2017 Dec 1)
    • (2014) AJP Ren Physiol , vol.306 , pp. F188-F193
    • Rieg, T.1    Masuda, T.2    Gerasimova, M.3    Mayoux, E.4    Platt, K.5    Powell, D.R.6    Thomson, S.C.7    Koepsell, H.8    Vallon, V.9
  • 103
    • 84921374064 scopus 로고    scopus 로고
    • The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
    • PID: 25341005 1
    • Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–70. Available: http://www.ncbi.nlm.nih.gov/pubmed/25341005 (accessed 2017 Dec 1)
    • (2015) Annu Rev Med , vol.66 , pp. 255-270
    • Vallon, V.1
  • 104
    • 84880012343 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus
    • PID: 23463735
    • Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2013;29:347–56. Available: http://doi.wiley.com/10.1002/dmrr.2403 (accessed 2017 Dec 1)
    • (2013) Diabetes Metab Res Rev , vol.29 , pp. 347-356
    • Raskin, P.1
  • 105
    • 85018663946 scopus 로고    scopus 로고
    • Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: an overview for the primary care physician
    • Dandona P, Chaudhuri A. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: an overview for the primary care physician. Int J Clin Pract. 2017;71:e12937. Available: http://doi.wiley.com/10.1111/ijcp.12937 (accessed 2017 Dec 7)
    • (2017) Int J Clin Pract , vol.71
    • Dandona, P.1    Chaudhuri, A.2
  • 106
    • 84971635917 scopus 로고    scopus 로고
    • Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
    • PID: 26998950 7
    • Song P, Onishi A, Koepsell H, Vallon V. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets. 2016;20:1109–25. Available: http://www.ncbi.nlm.nih.gov/pubmed/26998950 (accessed 2017 Dec 7)
    • (2016) Expert Opin Ther Targets , vol.20 , pp. 1109-1125
    • Song, P.1    Onishi, A.2    Koepsell, H.3    Vallon, V.4
  • 107
    • 85019123808 scopus 로고    scopus 로고
    • Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells
    • PID: 28499695 7
    • Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab. 2017;43:512–20. Available: http://www.ncbi.nlm.nih.gov/pubmed/28499695 (accessed 2017 Dec 7)
    • (2017) Diabetes Metab , vol.43 , pp. 512-520
    • Solini, A.1    Sebastiani, G.2    Nigi, L.3    Santini, E.4    Rossi, C.5    Dotta, F.6
  • 108
    • 84891534541 scopus 로고    scopus 로고
    • Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans
    • PID: 24065789 1
    • Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans. Diabetes. 2013;62:3324–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/24065789 (accessed 2017 Dec 1)
    • (2013) Diabetes , vol.62 , pp. 3324-3328
    • Abdul-Ghani, M.A.1    DeFronzo, R.A.2    Norton, L.3
  • 109
    • 84865479822 scopus 로고    scopus 로고
    • Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
    • PID: 22923645 1
    • Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61:2199–204. Available: http://www.ncbi.nlm.nih.gov/pubmed/22923645 (accessed 2017 Dec 1)
    • (2012) Diabetes , vol.61 , pp. 2199-2204
    • Liu, J.J.1    Lee, T.2    DeFronzo, R.A.3
  • 110
    • 84901198078 scopus 로고    scopus 로고
    • Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors
    • PID: 24631482 1
    • Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330–9. Available: http://linkinghub.elsevier.com/retrieve/pii/S1933171114000606 (accessed 2017 Dec 1)
    • (2014) J Am Soc Hypertens , vol.8 , pp. 330-339
    • Oliva, R.V.1    Bakris, G.L.2
  • 111
    • 84976259091 scopus 로고    scopus 로고
    • SGLT2 inhibitors in the management of type 2 diabetes
    • PID: 27270407
    • Monica Reddy RP, Inzucchi SE. SGLT2 inhibitors in the management of type 2 diabetes. Endocrine. 2016;53:364–72. Available: http://link.springer.com/10.1007/s12020-016-0943-4 (accessed 2017 Dec 1)
    • (2016) Endocrine , vol.53 , pp. 364-372
    • Monica Reddy, R.P.1    Inzucchi, S.E.2
  • 113
    • 85019731757 scopus 로고    scopus 로고
    • Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)
    • PID: 28522450 15
    • Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249–59. Available: http://www.ncbi.nlm.nih.gov/pubmed/28522450 (accessed 2018 Jan 15)
    • (2017) Circulation , vol.136 , pp. 249-259
    • Kosiborod, M.1    Cavender, M.A.2    Fu, A.Z.3    Wilding, J.P.4    Khunti, K.5    Holl, R.W.6    Norhammar, A.7    Birkeland, K.I.8    Jørgensen, M.E.9    Thuresson, M.10    Arya, N.11    Bodegård, J.12    Hammar, N.13    Fenici, P.14
  • 114
    • 85032165629 scopus 로고    scopus 로고
    • Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials
    • PID: 29061576 15
    • Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136:1643–58. Available: http://www.ncbi.nlm.nih.gov/pubmed/29061576 (accessed 2018 Jan 15)
    • (2017) Circulation , vol.136 , pp. 1643-1658
    • Lytvyn, Y.1    Bjornstad, P.2    Udell, J.A.3    Lovshin, J.A.4    Cherney, D.Z.I.5
  • 115
    • 84959553475 scopus 로고    scopus 로고
    • Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes
    • PID: 26620250 7
    • Muskiet MHA, van Bommel EJ, van Raalte DH. Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes. Lancet Diabetes Endocrinol. 2016;4:188–9. Available: http://linkinghub.elsevier.com/retrieve/pii/S221385871500457X (accessed 2017 Dec 7)
    • (2016) Lancet Diabetes Endocrinol , vol.4 , pp. 188-189
    • Muskiet, M.H.A.1    van Bommel, E.J.2    van Raalte, D.H.3
  • 116
    • 84872158502 scopus 로고    scopus 로고
    • Vascular complications of diabetes: mechanisms of injury and protective factors
    • PID: 23312281 10
    • Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17:20–33. Available: http://www.ncbi.nlm.nih.gov/pubmed/23312281 (accessed 2017 Dec 10)
    • (2013) Cell Metab , vol.17 , pp. 20-33
    • Rask-Madsen, C.1    King, G.L.2
  • 122
    • 84964695799 scopus 로고    scopus 로고
    • Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists
    • PID: 25338737 1
    • Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol. 2014;13:142. Available: http://www.ncbi.nlm.nih.gov/pubmed/25338737 (accessed 2017 Dec 1)
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 142
    • Saraiva, F.K.1    Sposito, A.C.2
  • 123
    • 84861322287 scopus 로고    scopus 로고
    • Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes
    • PID: 22204436 1
    • Yamagishi S, Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des. 2011;17:4379–85. Available: http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1381-6128&volume=17&issue=38&spage=4379 (accessed 2017 Dec 1)
    • (2011) Curr Pharm Des , vol.17 , pp. 4379-4385
    • Yamagishi, S.1    Matsui, T.2
  • 124
    • 84865438872 scopus 로고    scopus 로고
    • NADPH oxidase NOX2 defines a new antagonistic role for reactive oxygen species and cAMP/PKA in the regulation of insulin secretion
    • PID: 22933115
    • Li N, Li B, Brun T, Deffert-Delbouille C, Mahiout Z, Daali Y, et al. NADPH oxidase NOX2 defines a new antagonistic role for reactive oxygen species and cAMP/PKA in the regulation of insulin secretion. Diabetes. 2012;61:2842–50. Available: http://diabetes.diabetesjournals.org/cgi/doi/10.2337/db12-0009 (accessed 2017 Dec 1)
    • (2012) Diabetes , vol.61 , pp. 2842-2850
    • Li, N.1    Li, B.2    Brun, T.3    Deffert-Delbouille, C.4    Mahiout, Z.5    Daali, Y.6    Ma, X.J.7    Krause, K.H.8    Maechler, P.9
  • 125
    • 84867643750 scopus 로고    scopus 로고
    • Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells
    • PID: 22982676 1
    • Kappe C, Holst JJ, Zhang Q, Sjöholm Å. Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. Biochem Biophys Res Commun. 2012;427:91–5. Available: http://www.ncbi.nlm.nih.gov/pubmed/22982676 (accessed 2017 Dec 1)
    • (2012) Biochem Biophys Res Commun , vol.427 , pp. 91-95
    • Kappe, C.1    Holst, J.J.2    Zhang, Q.3    Sjöholm, Å.4
  • 126
    • 78751481226 scopus 로고    scopus 로고
    • Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner
    • PID: 20978090 1
    • Mukai E, Fujimoto S, Sato H, Oneyama C, Kominato R, Sato Y, et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes. 2011;60:218–26. Available: http://www.ncbi.nlm.nih.gov/pubmed/20978090 (accessed 2017 Dec 1)
    • (2011) Diabetes , vol.60 , pp. 218-226
    • Mukai, E.1    Fujimoto, S.2    Sato, H.3    Oneyama, C.4    Kominato, R.5    Sato, Y.6    Sasaki, M.7    Nishi, Y.8    Okada, M.9    Inagaki, N.10
  • 127
    • 84875348947 scopus 로고    scopus 로고
    • Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways
    • PID: 23343509
    • Erdogdu O, Eriksson L, Xu H, Sjöholm A, Zhang Q, Nyström T. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol. 2013;50:229–41. Available: http://jme.endocrinology-journals.org/cgi/doi/10.1530/JME-12-0166 (accessed 2017 Dec 1)
    • (2013) J Mol Endocrinol , vol.50 , pp. 229-241
    • Erdogdu, O.1    Eriksson, L.2    Xu, H.3    Sjöholm, A.4    Zhang, Q.5    Nyström, T.6
  • 128
    • 0037422592 scopus 로고    scopus 로고
    • Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease
    • PID: 12515756 2
    • Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease. Circulation. 2003;107:139–46. Available: http://www.ncbi.nlm.nih.gov/pubmed/12515756 (accessed 2017 Dec 2)
    • (2003) Circulation , vol.107 , pp. 139-146
    • Lakatta, E.G.1    Levy, D.2
  • 129
    • 33846121333 scopus 로고    scopus 로고
    • Vascular cell senescence: contribution to atherosclerosis
    • PID: 17204661
    • Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res. 2007;100:15–26. Available: http://circres.ahajournals.org/cgi/doi/10.1161/01.RES.0000256837.40544.4a (accessed 2017 Dec 2)
    • (2007) Circ Res , vol.100 , pp. 15-26
    • Minamino, T.1    Komuro, I.2
  • 130
    • 0034129826 scopus 로고    scopus 로고
    • Angiotensin II, atherosclerosis, and aortic aneurysms
    • PID: 10841510 2
    • Berk BC, Haendeler J, Sottile J. Angiotensin II, atherosclerosis, and aortic aneurysms. J Clin Invest. 2000;105:1525–6. Available: http://www.jci.org/articles/view/9820 (accessed 2017 Dec 2)
    • (2000) J Clin Invest , vol.105 , pp. 1525-1526
    • Berk, B.C.1    Haendeler, J.2    Sottile, J.3
  • 131
    • 84987668892 scopus 로고    scopus 로고
    • Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study
    • PID: 27619983
    • Tanaka A, Murohara T, Taguchi I, Eguchi K, Suzuki M, Kitakaze M, et al. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol. 2016;15:133. Available: http://cardiab.biomedcentral.com/articles/10.1186/s12933-016-0449-7 (accessed 2018 Jan 15)
    • (2016) Cardiovasc Diabetol , vol.15 , pp. 133
    • Tanaka, A.1    Murohara, T.2    Taguchi, I.3    Eguchi, K.4    Suzuki, M.5    Kitakaze, M.6
  • 132
    • 80053508880 scopus 로고    scopus 로고
    • Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective
    • PID: 21869886 2
    • Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;2011:742719. Available: http://www.hindawi.com/journals/ije/2011/742719/ (accessed 2017 Dec 2)
    • (2011) Int J Endocrinol , vol.2011 , pp. 742719
    • Kakouros, N.1    Rade, J.J.2    Kourliouros, A.3    Resar, J.R.4
  • 133
    • 84905082673 scopus 로고    scopus 로고
    • Zucker diabetic fatty rats exhibit hypercoagulability and accelerated thrombus formation in the Arterio-Venous shunt model of thrombosis
    • PID: 24796819
    • Shang J, Chen Z, Wang M, Li Q, Feng W, Wu Y, et al. Zucker diabetic fatty rats exhibit hypercoagulability and accelerated thrombus formation in the Arterio-Venous shunt model of thrombosis. Thromb Res. 2014;134:433–9.
    • (2014) Thromb Res , vol.134 , pp. 433-439
    • Shang, J.1    Chen, Z.2    Wang, M.3    Li, Q.4    Feng, W.5    Wu, Y.6    Wu, W.7    Graziano, M.P.8    Chintala, M.9
  • 134
    • 84862853052 scopus 로고    scopus 로고
    • Chances and risks of SGLT2 inhibitors
    • Mayer P. Chances and risks of SGLT2 inhibitors. Naunyn Schmiedeberg's Arch Pharmacol. 2012;385:551–4.
    • (2012) Naunyn Schmiedeberg's Arch Pharmacol , vol.385 , pp. 551-554
    • Mayer, P.1
  • 136
    • 84901198078 scopus 로고    scopus 로고
    • Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors
    • Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330–9. 10.1016/j.jash.2014.02.003.
    • (2014) J Am Soc Hypertens , vol.8 , pp. 330-339
    • Oliva, R.V.1    Bakris, G.L.2
  • 138
    • 84976340181 scopus 로고    scopus 로고
    • A case of type 2 diabetes with a change from a non-dipper to a dipper blood pressure pattern by dapagliflozin
    • PID: 27302728 5
    • MORI H, OKADA Y, KAWAGUCHI M, TANAKA Y. A case of type 2 diabetes with a change from a non-dipper to a dipper blood pressure pattern by dapagliflozin. J UOEH. 2016;38:149–53. Available: http://www.ncbi.nlm.nih.gov/pubmed/27302728 (accessed 2017 Dec 5)
    • (2016) J UOEH , vol.38 , pp. 149-153
    • Mori, H.1    Okada, Y.2    Kawaguchi, M.3    Tanaka, Y.4
  • 139
    • 84928196614 scopus 로고    scopus 로고
    • Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
    • PID: 25271206 5
    • Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/25271206 (accessed 2017 Dec 5)
    • (2015) Diabetes Care , vol.38 , pp. 420-428
    • Tikkanen, I.1    Narko, K.2    Zeller, C.3    Green, A.4    Salsali, A.5    Broedl, U.C.6    Woerle, H.J.7
  • 140
    • 85044513067 scopus 로고    scopus 로고
    • Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors
    • PID: 28496544
    • Sano M. Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors. J Clin Med Res. 2017;9:457–60.
    • (2017) J Clin Med Res , vol.9 , pp. 457-460
    • Sano, M.1
  • 141
    • 84920574327 scopus 로고    scopus 로고
    • Distal convoluted tubule
    • PID: 24855283 5
    • Subramanya AR, Ellison DH. Distal convoluted tubule. Clin J Am Soc Nephrol. 2014;9:2147–63. Available: http://www.ncbi.nlm.nih.gov/pubmed/24855283 (accessed 2017 Dec 5)
    • (2014) Clin J Am Soc Nephrol , vol.9 , pp. 2147-2163
    • Subramanya, A.R.1    Ellison, D.H.2
  • 142
    • 1342322671 scopus 로고    scopus 로고
    • Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure
    • PID: 15076184 5
    • Cuspidi C, Meani S, Salerno M, Valerio C, Fusi V, Severgnini B, et al. Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure. J Hypertens. 2004;22:273–80. Available: http://www.ncbi.nlm.nih.gov/pubmed/15076184 (accessed 2017 Dec 5)
    • (2004) J Hypertens , vol.22 , pp. 273-280
    • Cuspidi, C.1    Meani, S.2    Salerno, M.3    Valerio, C.4    Fusi, V.5    Severgnini, B.6    Lonati, L.7    Magrini, F.8    Zanchetti, A.9
  • 143
    • 0034084523 scopus 로고    scopus 로고
    • Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus
    • PID: 10872534 5
    • Sturrock ND, George E, Pound N, Stevenson J, Peck GM, Sowter H. Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med. 2000;17:360–4. Available: http://www.ncbi.nlm.nih.gov/pubmed/10872534 (accessed 2017 Dec 5)
    • (2000) Diabet Med , vol.17 , pp. 360-364
    • Sturrock, N.D.1    George, E.2    Pound, N.3    Stevenson, J.4    Peck, G.M.5    Sowter, H.6
  • 144
    • 0027466034 scopus 로고
    • Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetes. Prevalence of impaired diurnal blood pressure patterns
    • PID: 8427656 5
    • Fogari R, Zoppi A, Malamani GD, Lazzari P, Destro M, Corradi L. Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetes. Prevalence of impaired diurnal blood pressure patterns. Am J Hypertens. 1993;6:1–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/8427656 (accessed 2017 Dec 5)
    • (1993) Am J Hypertens , vol.6 , pp. 1-7
    • Fogari, R.1    Zoppi, A.2    Malamani, G.D.3    Lazzari, P.4    Destro, M.5    Corradi, L.6
  • 146
    • 77951968716 scopus 로고    scopus 로고
    • Mechanisms of obesity-induced hypertension
    • PID: 20442753 5
    • Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33:386–93. Available: http://www.ncbi.nlm.nih.gov/pubmed/20442753 (accessed 2017 Dec 5)
    • (2010) Hypertens Res , vol.33 , pp. 386-393
    • Kotsis, V.1    Stabouli, S.2    Papakatsika, S.3    Rizos, Z.4    Parati, G.5
  • 147
    • 84977275146 scopus 로고    scopus 로고
    • A role for circadian clock in metabolic disease
    • PID: 26888117 5
    • Shimizu I, Yoshida Y, Minamino T. A role for circadian clock in metabolic disease. Hypertens Res. 2016;39:483–91. Available: http://www.ncbi.nlm.nih.gov/pubmed/26888117 (accessed 2017 Dec 5)
    • (2016) Hypertens Res , vol.39 , pp. 483-491
    • Shimizu, I.1    Yoshida, Y.2    Minamino, T.3
  • 148
    • 84867136387 scopus 로고    scopus 로고
    • Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
    • Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. AJP Ren Physiol. 2012;303:F963–71. Available: http://ajprenal.physiology.org/cgi/doi/10.1152/ajprenal.00259.2012 (accessed 2017 Dec 1)
    • (2012) AJP Ren Physiol , vol.303 , pp. F963-F971
    • Rieg, T.1    Gerasimova, M.2    Murray, F.3    Masuda, T.4    Tang, T.5    Rose, M.6    Drucker, D.J.7    Vallon, V.8
  • 149
    • 33947584619 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells
    • PID: 17276524 5
    • Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141:120–8. Available: http://linkinghub.elsevier.com/retrieve/pii/S0167011506002734 (accessed 2017 Dec 5)
    • (2007) Regul Pept , vol.141 , pp. 120-128
    • Schlatter, P.1    Beglinger, C.2    Drewe, J.3    Gutmann, H.4
  • 150
    • 85031929302 scopus 로고    scopus 로고
    • Renal and cardiovascular effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop diuretics in diabetic patients with chronic heart failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
    • PID: 29042392 7
    • Mordi NA, Mordi IR, Singh JS, Baig F, Choy A-M, McCrimmon RJ, et al. Renal and cardiovascular effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop diuretics in diabetic patients with chronic heart failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open. 2017;7:e018097. Available: http://www.ncbi.nlm.nih.gov/pubmed/29042392 (accessed 2017 Dec 7)
    • (2017) BMJ Open , vol.7
    • Mordi, N.A.1    Mordi, I.R.2    Singh, J.S.3    Baig, F.4    Choy, A.-M.5    McCrimmon, R.J.6
  • 152
    • 84877317750 scopus 로고    scopus 로고
    • GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
    • PID: 23542788
    • Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567–75. Available: http://www.nature.com/doifinder/10.1038/nm.3128 (accessed 2017 Dec 7)
    • (2013) Nat Med , vol.19 , pp. 567-575
    • Kim, M.1    Platt, M.J.2    Shibasaki, T.3    Quaggin, S.E.4    Backx, P.H.5    Seino, S.6    Simpson, J.A.7    Drucker, D.J.8
  • 153
    • 43249089631 scopus 로고    scopus 로고
    • Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and independent pathways
    • PID: 18427132 7
    • Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and independent pathways. Circulation. 2008;117:2340–50. Available: http://www.ncbi.nlm.nih.gov/pubmed/18427132 (accessed 2017 Dec 7)
    • (2008) Circulation , vol.117 , pp. 2340-2350
    • Ban, K.1    Noyan-Ashraf, M.H.2    Hoefer, J.3    Bolz, S.-S.4    Drucker, D.J.5    Husain, M.6
  • 154
    • 28144434185 scopus 로고    scopus 로고
    • Type II diabetes mellitus is independently associated with non-rheumatic aortic valve stenosis or regurgitation
    • 7
    • Movahed M-R, Hashemzadeh M, Jamal MM. Type II diabetes mellitus is independently associated with non-rheumatic aortic valve stenosis or regurgitation. CHEST J. 2005;128:3568–71. Available: http://www.ncbi.nlm.nih.gov/pubmed/16304314 (accessed 2017 Dec 7)
    • (2005) CHEST J , vol.128 , pp. 3568-3571
    • Movahed, M.-R.1    Hashemzadeh, M.2    Jamal, M.M.3
  • 155
    • 37549068962 scopus 로고    scopus 로고
    • Pathogenic mechanisms of pulmonary arterial hypertension
    • PID: 17950310 7
    • Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2008;44:14–30. Available: http://www.ncbi.nlm.nih.gov/pubmed/17950310 (accessed 2017 Dec 7)
    • (2008) J Mol Cell Cardiol , vol.44 , pp. 14-30
    • Chan, S.Y.1    Loscalzo, J.2
  • 156
    • 0034050078 scopus 로고    scopus 로고
    • Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent
    • PID: 10780668 7
    • Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, et al. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. Lab Investig. 2000;80:513–27. Available: http://www.ncbi.nlm.nih.gov/pubmed/10780668 (accessed 2017 Dec 7)
    • (2000) Lab Investig , vol.80 , pp. 513-527
    • Fiordaliso, F.1    Li, B.2    Latini, R.3    Sonnenblick, E.H.4    Anversa, P.5    Leri, A.6    Kajstura, J.7
  • 157
    • 84861099242 scopus 로고    scopus 로고
    • Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor Axis
    • PID: 22474255
    • Patel VB, Bodiga S, Basu R, Das SK, Wang W, Wang Z, et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor Axis. Circ Res. 2012;110:1322–35. Available: http://circres.ahajournals.org/cgi/doi/10.1161/CIRCRESAHA.112.268029 (accessed 2017 Dec 7)
    • (2012) Circ Res , vol.110 , pp. 1322-1335
    • Patel, V.B.1    Bodiga, S.2    Basu, R.3    Das, S.K.4    Wang, W.5    Wang, Z.6    Lo, J.7    Grant, M.B.8    Zhong, J.9    Kassiri, Z.10    Oudit, G.Y.11
  • 158
    • 84880850027 scopus 로고    scopus 로고
    • Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
    • PID: 23668478 7
    • Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–62. Available: http://www.ncbi.nlm.nih.gov/pubmed/23668478 (accessed 2017 Dec 7)
    • (2013) Diabetes Obes Metab , vol.15 , pp. 853-862
    • Lambers Heerspink, H.J.1    de Zeeuw, D.2    Wie, L.3    Leslie, B.4    List, J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.